AUTL Autolus Therapeutics plc
Price Chart
Executive Summary
Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product, a prestigious industry recognition for its T cell therapy innovation. The award is a non-financial validation of the company's scientific platform and commercial-stage status, but does not directly impact revenue, pipeline milestones, or near-term financials.
Actionable Insight
The award is a positive reputational signal but lacks financial or operational catalysts. Monitor for upcoming pipeline data readouts or regulatory milestones that could drive valuation.
Key Facts
- Autolus won the 2026 Prix Galien UK Award for Best Biotechnology Product.
- The award is selected by a 12-expert UK Awards Committee.
- Prix Galien is described as the equivalent of the Nobel Prize in biopharmaceutical research.
- Autolus is a commercial-stage biopharmaceutical company with a marketed therapy and pipeline in hematological malignancies, solid tumors, and autoimmune diseases.
Financial Impact
No financial figures disclosed; award provides reputational benefit but no direct revenue or cost impact.
Risk Factors
- Award does not change commercial traction, competitive positioning, or regulatory timelines.
- No financial guidance or pipeline updates provided in the release.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310914 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Press Release
| $1.57 awaiting T+5 | awaiting T+5 | — | $1.56 (−0.64%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $1.56 awaiting T+5 | awaiting T+5 | — | $1.56 (−0.32%) |
|
Jun 9, 2026
4d ago
|
8-K
| $1.45 awaiting T+5 | awaiting T+5 | — | $1.56 (−7.59%) |
|
May 21, 2026
22d ago
|
Press Release
| $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.56 (−8.24%) |
|
May 14, 2026
4w ago
|
8-K
| $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.56 (−1.89%) |
|
May 14, 2026
4w ago
|
Press Release
| $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.56 (−1.89%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $1.60 $1.42 | ▼ −11.56% | ▼ −11.62% | $1.56 (−2.50%) |
|
Apr 8, 2026
9w ago
|
8-K
| $1.47 $1.61 | ▲ +9.52% | ▲ +6.34% | $1.56 (+6.12%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $1.51 $1.32 | ▼ −12.58% | ▼ −9.93% | $1.56 (+3.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access